Autopsies of supercentenarians suggest that transthyretin amyloidosis and consequent heart failure is the limiting process. Since methods of removing transthyre

Autopsies of supercentenarians suggest that transthyretin amyloidosis and consequent heart failure is the limiting process. Since methods of removing transthyretin amyloid are somewhere in the pipeline (Covalent Bioscience, Pentraxin Therapeutics, etc), this limit won't be around a couple of decades from now. But you are right; next to no-one cares. The thing that is driving anti-amyloid work in this case is inherited disease in which there is excessive amyloid formation at younger ages, and the growing realization that 10% or more of people who die from heart disease in the 60+ age range are doing so because of normal levels of transthyretin amyloid deposition.